The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.
Jennifer Bickel has been named the inaugural vice president and chief wellness officer at the University of Texas MD Anderson Cancer Center. She will begin on Jan. 6, 2025.
The University of Texas MD Anderson Cancer Center hosted its ninth annual Boot Walk to End Cancer fundraising event on Nov. 2, in the Texas Medical Center. This year, the Boot Walk’s 7,000+ in-person participants and 1,200+ virtual participants from Houston and around the world joined together to raise $1.4 million to support the institution’s mission to end cancer.
The University of Texas MD Anderson Cancer Center announced an agreement to become a Women’s Cancer Partner with the Union for International Cancer Control, marking a significant collaboration to improve breast and cervical cancer care worldwide.
The University of Texas MD Anderson Cancer Center announced its first-ever academic journal, Advances in Cancer Education & Quality Improvement. The journal will publish research, training program summaries, and quality improvement interventions for the oncology provider community.
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
Tumors are able to form without any DNA mutations, according to a recent proof-of-principle study performed in flies. Epigenetic changes alone—even temporary alterations—induced permanent cancer cell fate.
The Cancer Prevention and Research Institute of Texas approved $60.6 million in grants.
The AMADEUS clinical trial sheds light on how biomarkers can predict how patients respond to immune checkpoint inhibitor treatments like nivolumab and ipilimumab.
Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.
